Schorno Dean L's Form 4 filing
Rigel Pharmaceuticals Inc (RIGL) · filed Feb 6, 2025
- Accession no.
- 0000905148-25-000413
- Filed
- Feb 6, 2025
- Trade date
- Feb 4-5, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $80.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schorno Dean LCIK 0001509688 | Officer (EVP & Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 4, 2025 | Common Stock | SSaleDisposed | −2,036 | $20.92 | −$42,593.12 | 58,969 | Direct | |
| Feb 5, 2025 | Common Stock | SSaleDisposed | −1,734 | $21.93 | −$38,026.62 | 57,235 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.